Form 4: Agios CEO Sells Shares for Tax Obligation

Agios Pharmaceuticals CEO Brian Goff sold 11,085 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Brian Goff, Chief Executive Officer and Director of Agios Pharmaceuticals, Inc. (AGIO), reported changes in his beneficial ownership of company common stock.
• On August 8, 2025, 22,691 shares of common stock were acquired at a price of $0, resulting from the vesting of restricted stock units (RSUs).
• Concurrently, 11,085 shares of common stock were disposed of at a price of $36.67 per share.
• This disposition was specifically to cover tax withholding obligations associated with the RSU vesting.
• The transaction was executed pursuant to a pre-arranged Rule 10b5-1(c) plan, which was part of the restricted stock unit agreement dated August 8, 2022.
• Following these transactions, Brian Goff's direct beneficial ownership stands at 123,528 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. This Form 4 reports a routine, pre-scheduled transaction for tax purposes related to executive compensation. It does not provide new information that would significantly alter the investment thesis or indicate a change in the company's fundamental performance or management's confidence.

Positives

• The sale of shares was pre-planned under a Rule 10b5-1(c) plan, indicating it was a non-discretionary transaction and not based on new, undisclosed material information.
• The transaction is a routine event associated with executive equity compensation, specifically the vesting of restricted stock units and the subsequent sale to cover tax liabilities.

Negatives

• A reduction in the direct beneficial ownership of common stock by the Chief Executive Officer, although for a specific tax-related purpose.

Future Outlook

This filing, a Form 4, reports changes in insider beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This transaction is a routine insider filing common across all industries, reflecting the standard practice of executives selling a portion of their vested equity awards to cover tax liabilities. It does not indicate any specific trends or shifts within the biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• The practice of executives selling shares to cover tax obligations upon the vesting of restricted stock units is a standard component of executive compensation plans across publicly traded companies, including those in the biotechnology sector.
• The use of a Rule 10b5-1(c) plan for such sales is also a common and recommended practice, aligning with corporate governance best practices to mitigate concerns about insider trading.

Related Party Transactions

• The reported transactions involve the company's Chief Executive Officer and Director, Brian Goff, and are considered related party transactions as they pertain to his equity compensation and beneficial ownership in the company.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a common occurrence and typically has minimal impact on shareholder sentiment or the company's stock price, as it is not a discretionary sale based on new information.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this routine insider transaction.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Brian Goff, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Executive Compensation, Tax Withholding, Rule 10b5-1